AlphaMark Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $4K | Hold |
34
| – | – | ﹤0.01% | 531 |
|
|
2024
Q3 | $4K | Hold |
34
| – | – | ﹤0.01% | 591 |
|
|
2024
Q2 | $4K | Hold |
34
| – | – | ﹤0.01% | 636 |
|
|
2024
Q1 | $4K | Hold |
34
| – | – | ﹤0.01% | 621 |
|
|
2023
Q4 | $4K | Hold |
34
| – | – | ﹤0.01% | 610 |
|
|
2023
Q3 | $4K | Hold |
34
| – | – | ﹤0.01% | 608 |
|
|
2023
Q2 | $4K | Hold |
34
| – | – | ﹤0.01% | 508 |
|
|
2023
Q1 | $5K | Hold |
34
| – | – | ﹤0.01% | 499 |
|
|
2022
Q4 | $5K | Hold |
34
| – | – | ﹤0.01% | 452 |
|
|
2022
Q3 | $5K | Hold |
34
| – | – | ﹤0.01% | 509 |
|
|
2022
Q2 | $5K | Hold |
34
| – | – | ﹤0.01% | 468 |
|
|
2022
Q1 | $5K | Hold |
34
| – | – | ﹤0.01% | 475 |
|
|
2021
Q4 | $4K | Hold |
34
| – | – | ﹤0.01% | 483 |
|
|
2021
Q3 | $4K | Hold |
34
| – | – | ﹤0.01% | 488 |
|
|
2021
Q2 | $6K | Hold |
34
| – | – | ﹤0.01% | 443 |
|
|
2021
Q1 | $6K | Hold |
34
| – | – | ﹤0.01% | 424 |
|
|
2020
Q4 | $6K | Hold |
34
| – | – | ﹤0.01% | 410 |
|
|
2020
Q3 | $5K | Hold |
34
| – | – | ﹤0.01% | 434 |
|
|
2020
Q2 | $4K | Hold |
34
| – | – | ﹤0.01% | 451 |
|
|
2020
Q1 | $3K | Hold |
34
| – | – | ﹤0.01% | 424 |
|
|
2019
Q4 | $5K | Hold |
34
| – | – | ﹤0.01% | 407 |
|
|
2019
Q3 | $4K | Hold |
34
| – | – | ﹤0.01% | 417 |
|
|
2019
Q2 | $5K | Hold |
34
| – | – | ﹤0.01% | 414 |
|
|
2019
Q1 | $5K | Hold |
34
| – | – | ﹤0.01% | 407 |
|
|
2018
Q4 | $4K | Hold |
34
| – | – | ﹤0.01% | 404 |
|
|
2018
Q3 | $6K | Hold |
34
| – | – | ﹤0.01% | 406 |
|
|
2018
Q2 | $6K | Hold |
34
| – | – | ﹤0.01% | 422 |
|
|
2018
Q1 | $5K | Hold |
34
| – | – | ﹤0.01% | 419 |
|
|
2017
Q4 | $5K | Hold |
34
| – | – | ﹤0.01% | 413 |
|
|
2017
Q3 | $5K | Hold |
34
| – | – | ﹤0.01% | 402 |
|
|
2017
Q2 | $5K | Hold |
34
| – | – | ﹤0.01% | 420 |
|
|
2017
Q1 | $5K | Sell |
34
-183
| -84% | -$23.8K | ﹤0.01% | 403 |
|
|
2016
Q4 | $24K | Sell |
217
-25,070
| -99% | -$2.79M | 0.01% | 227 |
|
|
2016
Q3 | $3.07M | Buy |
25,287
+544
| +2% | +$73.3K | 1.55% | 25 |
|
|
2016
Q2 | $3.5M | Sell |
24,743
-713
| -3% | -$105K | 2.06% | 17 |
|
|
2016
Q1 | $3.32M | Buy |
25,456
+8,757
| +52% | +$1.09M | 1.77% | 20 |
|
|
2015
Q4 | $2.35M | Sell |
16,699
-7,809
| -32% | -$1.08M | 1.19% | 31 |
|
|
2015
Q3 | $3.25M | Buy |
24,508
+506
| +2% | +$87.1K | 1.81% | 18 |
|
|
2015
Q2 | $4.23M | Sell |
24,002
-95
| -0.4% | -$17.1K | 2.38% | 8 |
|
|
2015
Q1 | $4.16M | Buy |
24,097
+2,428
| +11% | +$417K | 2.33% | 8 |
|
|
2014
Q4 | $3.55M | Sell |
21,669
-551
| -2% | -$91.5K | 2.19% | 15 |
|
|
2014
Q3 | $3.57M | Sell |
22,220
-605
| -3% | -$93K | 2.25% | 12 |
|
|
2014
Q2 | $3.36M | Buy |
22,825
+1,679
| +8% | +$233K | 2% | 15 |
|
|
2014
Q1 | $2.93M | Buy |
+21,146
| New | +$3.18M | 1.81% | 24 |
|
Other funds holding JAZZ
EC
AlphaMark Advisors's JAZZ Position: Q4 2024 in Review
AlphaMark Advisors held its Jazz Pharmaceuticals (JAZZ) position steady in Q4 2024 at 34 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #531.
AlphaMark Advisors first reported a position in JAZZ in Q1 2014 and has held it in 44 quarters since. The position peaked at $4.23M in Q2 2015. 508 funds tracked by Wall St. Rank hold JAZZ as of Q4 2024.
- AlphaMark Advisors held 34 shares of Jazz Pharmaceuticals worth $4K as of Q4 2024.
- AlphaMark Advisors left its Jazz Pharmaceuticals share count unchanged in Q4 2024.
- Jazz Pharmaceuticals made up ﹤0.01% of AlphaMark Advisors's portfolio in Q4 2024, its #531 holding.
- AlphaMark Advisors first reported a position in Jazz Pharmaceuticals in Q1 2014 and has held it in 44 quarters since.
- AlphaMark Advisors's Jazz Pharmaceuticals position peaked at $4.23M in Q2 2015.
- 508 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2024.
Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.